Navigation Links
Echo Therapeutics Announces Second Quarter 2011 Financial Results
Date:8/12/2011

ith Echo's CEO, Dr. Patrick Mooney, was posted on May 31, 2011.  On June 8, 2011, Dr. Stanley Nasraway, Director of the Surgical Intensive Care Units at Tufts Medical Center and ICU glycemic control thought leader discussed Echo's Symphony tCGM System in his BioMedReports article, "Tight Glycemic Control: What do we really know, and what should we expect?"
  • Echo's common stock began trading on The NASDAQ Capital Market on June 29, 2011. Echo continues to trade under the ticker symbol "ECTE."
  • Equity research coverage of Echo was initiated by Morgan Joseph TriArtisan, JMP Securities, Feltl and Company, Chardan Capital Markets, and Noble Financial Capital Markets.

  • "Our progress during the first half of 2011 is exemplified by the continued advancement of our Symphony tCGM System, the appointment of Chris Schnittker as Chief Financial Officer, and the move to Nasdaq," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "As we head into the second half of the year, our focus is to drive Symphony through clinical trials and, ultimately, to the market.  With several important milestones still ahead, we look forward to continued progress and increased shareholder value."

    First Quarter 2011 Financial ResultsFor the six months ended June 30, 2011, Echo reported approximately $243,000 in licensing revenue compared to $182,000 revenue in the first half of 2010. The company increased operating expenses by 5% to $3.8 million compared to $3.6 million during the first half of 2010. This increase included an 11% increase in research and development and almost no change in selling, general and administrative expenses. The net loss and ne
    '/>"/>

    SOURCE Echo Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
    2. Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription
    3. Echo Therapeutics Unveils Symphony tCGM Demonstration Video
    4. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
    5. Echo Therapeutics Announces Multiple Patents and Trademark Grants
    6. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
    7. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
    8. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
    9. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
    10. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
    11. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
    (Date:8/3/2015)... PARK, N.J. , Aug. 3, 2015 ... and secondary endpoints in a phase III study (COMPOSE ... adult patients with chronic non-cancer pain. Naldemedine is an ... is the third Phase III trial in which naldemedine ... Study results showed that a 0.2 mg tablet of ...
    (Date:8/3/2015)... Aug. 3, 2015  Encision Inc. (PK:ECIA), a medical ... stray electrosurgical burns in minimally invasive surgery, today announced ... ended June 30, 2015. The Company posted ... net loss of $213 thousand, or $(0.02) per share. ... for a net loss of $202 thousand, or $(0.02) ...
    Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
    ... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... on the development of zinc finger DNA-binding protein (ZFP) Therapeutics® ... collaborators at the 14th Annual Meeting of the American Society ... in Seattle from May 18-21, 2011. "Sangamo,s ...
    ... Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ), ... clinical data highlighting the safety profile of EXPAREL™ ... the 2011 International Anesthesia Research Society (IARS) Annual ... Comprehensive, program-wide safety data for EXPAREL will be ...
    Cached Medicine Technology:Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 2Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 3Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 5
    (Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July ... diet leads to one pound of weight loss may not be accurate. While this system ... to one pound of fat varies – based both on the individual and at what ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to ... related claims in which a claimant alleged to have suffered an arterial blood clot ... birth control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. ...
    (Date:8/3/2015)... ... August 03, 2015 , ... ... MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate ... BESLER Consulting's campaign for the launch of their Readmissions Analytics product was selected ...
    (Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
    (Date:8/3/2015)... , ... August 03, 2015 , ... ... notes that while an overwhelming number of Hispanics believe people can positively ... overwhelming 70 percent of participants queried said making diet changes was important. Far ...
    Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
    ... ... the highest honors in the industry. , ... (PRWEB) March 8, 2010 -- The Sturge-Weber Foundation honored renowned dermatologist Dr. David J. Goldberg with ... 2010. Dr. Goldberg is a pioneer in the field of dermatology and director ...
    ... ... ... ... ...
    ... developed a new mathematical approach to analyze molecular data ... when combined with well-established techniques, readily identifies changes in ... potential to distinguish between health and disease states. ... Ph.D., of Stanford University, Calif., the team of investigators ...
    ... Doctors should do more to explain test results, researchers find ... do a better job of explaining genomic test results to ... which analyzes 21 genes in breast tumors removed during surgery ... can help guide decisions about the use of chemotherapy in ...
    ... , ... ... ... ...
    ... , ... ... ... ...
    Cached Medicine News:Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 2Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 3Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 2Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 3Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 4Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 5Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 6Health News:New approach to immune cell analysis seen as first step to better distinguish health and disease 2Health News:New approach to immune cell analysis seen as first step to better distinguish health and disease 3Health News:Breast Cancer Patients Often Confused by Genomic Testing 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 3Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 4Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 5Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 2Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 3Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 4Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 5
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: